Ferrante, M. Et Al. 2024. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. The Lancet , vol.404, no.10470 , 2423-2436.

Ferrante, M., D'Haens, G., Jairath, V., Danese, S., Chen, M., Ghosh, S., ... Hisamatsu, T.(2024). Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. The Lancet , vol.404, no.10470, 2423-2436.

Ferrante, Marc Et Al. "Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study," The Lancet , vol.404, no.10470, 2423-2436, 2024

Ferrante, Marc Et Al. "Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study." The Lancet , vol.404, no.10470, pp.2423-2436, 2024

Ferrante, M. Et Al. (2024) . "Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study." The Lancet , vol.404, no.10470, pp.2423-2436.

@article{article, author={Marc Ferrante Et Al. }, title={Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study}, journal={The Lancet}, year=2024, pages={2423-2436} }